Panel: Winning the next wave of ATMP R&D: What Europe must resolve to compete on speed, scale and return

Speed breaks first: Why Europe still loses ATMP programmes at the trial-start and scale-up stages and what can be fixed in the next 12 months around approvals, site readiness and cross-border trial execution.

Scale without fragmentation: How disjointed manufacturing capacity, inconsistent incentives and weak CDMO coordination slow R&D momentum and what more joined-up European models could unlock faster progression from clinic to commercial.

Return signals matter: How reimbursement uncertainty, grant complexity and IP anxiety dilute investor confidence and which policy and payer signals would materially improve Europe’s risk-reward profile for ATMP R&D.

Where innovation leaks out: Identifying the points where advanced therapies quietly leave Europe (post-Phase I/II, before pivotal trials, pre-commercial scale-up) and how to retain them without protectionism.